|Institutional Source||Beutler Lab|
|Gene Name||interleukin 20 receptor, alpha|
Ncbi RefSeq: NM_172786.2; MGI:3605069
|Essential gene?||Non essential (E-score: 0.000)|
|Stock #||R4559 (G1)|
|Chromosomal Location||19712570-19760053 bp(+) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||A to G at 19749284 bp (GRCm38)|
|Amino Acid Change||Threonine to Alanine at position 104 (T104A)|
|Ref Sequence||ENSEMBL: ENSMUSP00000020185 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000020185] [ENSMUST00000217389]|
AA Change: T104A
PolyPhen 2 Score 0.986 (Sensitivity: 0.74; Specificity: 0.96)
AA Change: T104A
|Meta Mutation Damage Score||0.5845|
|Coding Region Coverage||
|Validation Efficiency||100% (56/56)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes a member of the type II cytokine receptor family. The encoded protein is a subunit of the receptor for interleukin 20, a cytokine that may be involved in epidermal function. The interleukin 20 receptor is a heterodimeric complex consisting of the encoded protein and interleukin 20 receptor beta. This gene and interleukin 20 receptor beta are highly expressed in skin, and are upregulated in psoriasis. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
PHENOTYPE: Mice homozygous for a knock-out allele exhibit increased bone mineral density, impaired osteoclast differentiation, and resistance to ovariectomized-inducced bone loss. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Il20ra||
(F):5'- ACCAACAGCAAAAGTGGATCTG -3'
(R):5'- AGTTGCCTATGAGGACAGAATATC -3'
(F):5'- GCATCTGTGTTTTGCTGAAGACAAAG -3'
(R):5'- TGCCTATGAGGACAGAATATCATACC -3'